# Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

> **NCT00694057** · PHASE2 · COMPLETED · sponsor: **Harbor Therapeutics** · enrollment: 164 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** HE3286
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00694057
- **Lead sponsor:** Harbor Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2011-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694057, "Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00694057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*